{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:51:54Z","timestamp":1774533114465,"version":"3.50.1"},"publisher-location":"Totowa, NJ","reference-count":51,"publisher":"Humana Press","isbn-type":[{"value":"9781627037570","type":"print"},{"value":"9781627037587","type":"electronic"}],"license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-1-62703-758-7_23","type":"book-chapter","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T17:02:02Z","timestamp":1392224522000},"page":"485-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Study 6. Transporter Case Studies: In Vitro Solutions for Translatable Outcomes"],"prefix":"10.1007","author":[{"given":"Sid","family":"Bhoopathy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Bode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vatsala","family":"Naageshwaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica A.","family":"Weiskircher-Hildebrandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael J.","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,17]]},"reference":[{"key":"23_CR1","unstructured":"Giacomini KM, Sugiyama Y (2005) In: Brunton L et al (eds). Goodman and Gilman\u2019s the pharmacological basis of therapeutics. McGraw\u2010Hill, New York, pp 41\u201370"},{"key":"23_CR2","unstructured":"US Food and Drug Administration (2012) Draft guidance for industry: drug interaction studies: study design, data analysis, implications for dosing and labeling recommendations"},{"key":"23_CR3","unstructured":"European Medicines Agency (2013) Guideline on the investigation of drug interactions"},{"issue":"2","key":"23_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejps.2010.03.009","volume":"40","author":"G Lappin","year":"2010","unstructured":"Lappin G et al (2010) Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 40(2):125\u2013131","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"23_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.clpt.2004.08.026","volume":"77","author":"N Yasui-Furukori","year":"2005","unstructured":"Yasui-Furukori N et al (2005) Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 77(1):17\u201323","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"23_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clpt.2004.10.005","volume":"77","author":"GK Dresser","year":"2005","unstructured":"Dresser GK, Kim RB, Bailey DG (2005) Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 77(3):170\u2013177","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"23_CR7","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1021\/mp200026v","volume":"8","author":"X Ming","year":"2011","unstructured":"Ming X, Knight BM, Thakker DR (2011) Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters. Mol Pharm 8(5):1677\u20131686","journal-title":"Mol Pharm"},{"issue":"11","key":"23_CR8","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1124\/dmd.112.045666","volume":"40","author":"J Li","year":"2012","unstructured":"Li J et al (2012) The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems. Drug Metab Dispos 40(11):2102\u20132108","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"23_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1124\/dmd.105.008615","volume":"34","author":"J Rautio","year":"2006","unstructured":"Rautio J et al (2006) In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34(5):786\u2013792","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"23_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1124\/dmd.107.019257","volume":"36","author":"J Enokizono","year":"2008","unstructured":"Enokizono J et al (2008) Quantitative investigation of the role of breast cancer resistance protein (Bcrp\/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab Dispos 36(6):995\u20131002","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"23_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1124\/dmd.104.001230","volume":"33","author":"A Doran","year":"2005","unstructured":"Doran A et al (2005) The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A\/1B knockout mouse model. Drug Metab Dispos 33(1):165\u2013174","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"23_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2174\/156802611795371288","volume":"11","author":"SL Mercer","year":"2011","unstructured":"Mercer SL, Coop A (2011) Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem 11(9):1157\u20131164","journal-title":"Curr Top Med Chem"},{"key":"23_CR13","first-page":"37","volume":"64","author":"LN Chan","year":"2008","unstructured":"Chan LN (2008) Opioid analgesics and the gastrointestinal tract. Pract Gastroenterol 64:37\u201350","journal-title":"Pract Gastroenterol"},{"issue":"5","key":"23_CR14","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1021\/mp100124f","volume":"7","author":"NM Zaki","year":"2010","unstructured":"Zaki NM, Artursson P, Bergstr\u00f6m CAS (2010) A modified physiological BCS for prediction of intestinal absorption in drug discovery. Mol Pharm 7(5):1478\u20131487","journal-title":"Mol Pharm"},{"issue":"5","key":"23_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2174\/1568026013395010","volume":"1","author":"IJ Hidalgo","year":"2001","unstructured":"Hidalgo IJ (2001) Assessing the absorption of new pharmaceuticals. Curr Top Med Chem 1(5):385\u2013401","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"23_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ijpharm.2004.10.007","volume":"288","author":"Q Wang","year":"2005","unstructured":"Wang Q et al (2005) Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 288(2):349\u2013359","journal-title":"Int J Pharm"},{"issue":"7","key":"23_CR17","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1124\/dmd.111.038075","volume":"39","author":"J Li","year":"2011","unstructured":"Li J et al (2011) Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 39(7):1196\u20131202","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"23_CR18","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1007\/s11095-009-9896-0","volume":"26","author":"P Matsson","year":"2009","unstructured":"Matsson P et al (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26(8):1816\u20131831","journal-title":"Pharm Res"},{"issue":"5","key":"23_CR19","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1124\/dmd.105.007534","volume":"34","author":"L Huang","year":"2005","unstructured":"Huang L et al (2005) ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistant protein. Drug Metab Dispos 34(5):738\u2013742","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"23_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham GG et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81\u201398","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"23_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2133\/dmpk.20.379","volume":"20","author":"N Kimura","year":"2005","unstructured":"Kimura N et al (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic. Drug Metab Pharmacokinet 20(5):379\u2013386","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"23_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM et al (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215\u2013236","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"23_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1208\/s12248-008-9068-x","volume":"10","author":"PV Balimane","year":"2008","unstructured":"Balimane PV et al (2008) P-gp inhibition potential in cell-based models: which \u201ccalculation\u201d method is the most accurate? AAPS J 10(4):577\u2013586","journal-title":"AAPS J"},{"issue":"3","key":"23_CR24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11095-009-0026-9","volume":"27","author":"T Tachibana","year":"2010","unstructured":"Tachibana T et al (2010) Model analysis of the concentration-dependant permeability of P-gp substrates. Pharm Res 27(3):442\u2013446","journal-title":"Pharm Res"},{"key":"23_CR25","unstructured":"Etravirine (package insert) (2008) Titusville, NJ: Janssen Pharmaceutical Inc"},{"issue":"3","key":"23_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1468-1293.2008.00668.x","volume":"10","author":"TN Kakuda","year":"2009","unstructured":"Kakuda TN et al (2009) Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers. HIV Med 10(3):173\u2013181","journal-title":"HIV Med"},{"key":"23_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011436344","author":"S Agarwal","year":"2012","unstructured":"Agarwal S, Arya V, Zhang L (2012) Review of P-gp inhibition data in recently approved new drug applications: utility of the proposed (I1)\/IC50 and (I2)\/IC50 criteria in the P-gp decision tree. J Clin Pharmacol. doi:10.1177\/0091270011436344","journal-title":"J Clin Pharmacol"},{"key":"23_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1046\/j.1365-2125.1999.00073.x","volume":"48","author":"KE Kenworthy","year":"1999","unstructured":"Kenworthy KE et al (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716\u2013727","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"23_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1124\/jpet.108.148411","volume":"329","author":"M Miyagawa","year":"2009","unstructured":"Miyagawa M et al (2009) The eighth and ninth transmembrane domains in organic anion transporting polypeptide 1B1 affect the transport kinetics of estrone-3-sulfate and estradiol-17-d-glucuronide. J Pharmacol Exp Ther 329(2):551\u2013557","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"23_CR30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M (2009) Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 158(3):693\u2013705","journal-title":"Br J Pharmacol"},{"issue":"7","key":"23_CR31","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2217\/14622416.8.7.787","volume":"8","author":"M Niemi","year":"2007","unstructured":"Niemi M (2007) Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8(7):787\u2013802","journal-title":"Pharmacogenomics"},{"issue":"1","key":"23_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1124\/jpet.104.068536","volume":"311","author":"Y Shitara","year":"2004","unstructured":"Shitara Y et al (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2\/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311(1):228\u2013236","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"23_CR33","doi-asserted-by":"publisher","first-page":"80A","DOI":"10.1016\/S0002-9149(05)80024-4","volume":"76","author":"JD Spence","year":"1995","unstructured":"Spence JD et al (1995) Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 76(2):80A\u201383A","journal-title":"Am J Cardiol"},{"issue":"6","key":"23_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","volume":"76","author":"SG Simonson","year":"2004","unstructured":"Simonson SG et al (2004) Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76(6):167\u2013177","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"23_CR35","first-page":"695","volume":"51","author":"O Ozdemir","year":"2000","unstructured":"Ozdemir O et al (2000) A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy\u2014a case report. Angiology 51(8):695\u2013697","journal-title":"Angiology"},{"issue":"12","key":"23_CR36","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1124\/dmd.30.12.1352","volume":"30","author":"JS Wang","year":"2002","unstructured":"Wang JS et al (2002) Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30(12):1352\u20131356","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"23_CR37","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1124\/dmd.106.012930","volume":"35","author":"J Noe","year":"2007","unstructured":"Noe J et al (2007) Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 35(8):1308\u20131314","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"23_CR38","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1023\/A:1013077609227","volume":"18","author":"I Tamai","year":"2001","unstructured":"Tamai I et al (2001) Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver specific OATP-C. Pharm Res 18(9):1262\u20131269","journal-title":"Pharm Res"},{"issue":"7","key":"23_CR39","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/dna.1997.16.871","volume":"16","author":"V Gorboulev","year":"1997","unstructured":"Gorboulev V et al (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16(7):871\u2013881","journal-title":"DNA Cell Biol"},{"key":"23_CR40","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.V134866","volume":"13","author":"H Motohashi","year":"2002","unstructured":"Motohashi H et al (2002) Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 13:866\u2013874","journal-title":"J Am Soc Nephrol"},{"key":"23_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/jpet.108.147918","volume":"329","author":"M Tsuda","year":"2009","unstructured":"Tsuda M et al (2009) Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 329:185\u2013191","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"23_CR42","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/j.1552-4604.1995.tb04033.x","volume":"35","author":"NC Sambol","year":"1995","unstructured":"Sambol NC et al (1995) Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 35(11):1094\u20131102","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"23_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1365-2125.1987.tb03090.x","volume":"23","author":"A Somogyi","year":"1987","unstructured":"Somogyi A et al (1987) Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23(5):545\u2013551","journal-title":"Br J Clin Pharmacol"},{"key":"23_CR44","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2337\/db07-1515","volume":"57","author":"I Bachmakov","year":"2008","unstructured":"Bachmakov I et al (2008) Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on OATPs and OCT1. Diabetes 57:1463\u20131469","journal-title":"Diabetes"},{"issue":"8","key":"23_CR45","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1023\/A:1019870831174","volume":"19","author":"MJ Dresser","year":"2002","unstructured":"Dresser MJ et al (2002) Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 19(8):1244\u20131247","journal-title":"Pharm Res"},{"issue":"3 pt 2","key":"23_CR46","first-page":"F597","volume":"258","author":"KD Lazaruk","year":"1990","unstructured":"Lazaruk KD, Wright SH (1990) MPP+ is transported by the TEA1-H1 exchanger of renal brush-border membrane vesicles. Am J Physiol 258(3 pt 2):F597\u2013F605","journal-title":"Am J Physiol"},{"issue":"1","key":"23_CR47","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0022-3565(25)39046-4","volume":"242","author":"PP Sokol","year":"1987","unstructured":"Sokol PP et al (1987) The neurotoxins 1-methyl-4-phenylpyridinium and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine are substrates for the organic cation transporter in renal brush border membrane vesicles. J Pharmacol Exp Ther 242(1):152\u2013157","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"23_CR48","first-page":"A1270","volume":"110","author":"RH Moseley","year":"1996","unstructured":"Moseley RH, Zuggar LJ (1996) The cationic neurotoxin, 1-methyl-4-phenylpyridinium (MPP1), is a substrate for the canalicular organic cation:H1 exchanger. Gastroenterology 110(1):A1270","journal-title":"Gastroenterology"},{"issue":"4","key":"23_CR49","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1152\/physrev.1993.73.4.765","volume":"73","author":"JB Pritchard","year":"1993","unstructured":"Pritchard JB, Miller DS (1993) Mechanisms mediating renal secretion of organic anions and cations. Physiol Rev 73(4):765\u2013796","journal-title":"Physiol Rev"},{"issue":"1","key":"23_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0304-4157(94)90018-3","volume":"1197","author":"KJ Ullrich","year":"1994","unstructured":"Ullrich KJ (1994) Specificity of transporters for \u2018organic anions\u2019 and \u2018organic cations\u2019 in the kidney. Biochim Biophys Acta 1197(1):45\u201362","journal-title":"Biochim Biophys Acta"},{"key":"23_CR51","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s00424-003-1089-9","volume":"447","author":"H Koepsell","year":"2004","unstructured":"Koepsell H, Endou H (2004) The SLC22 drug transporter family. Pflugers Arch 447:666\u2013676","journal-title":"Pflugers Arch"}],"container-title":["Methods in Molecular Biology","Enzyme Kinetics in Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-62703-758-7_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T21:02:20Z","timestamp":1746133340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-62703-758-7_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"ISBN":["9781627037570","9781627037587"],"references-count":51,"URL":"https:\/\/doi.org\/10.1007\/978-1-62703-758-7_23","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]},"assertion":[{"value":"17 January 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}